Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MannKind Corporation (MNKD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into MannKind’s operations as a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Among the key filings are Form 8-K current reports, which MannKind uses to describe material events. Recent 8-Ks document the completion of the acquisition of scPharmaceuticals, the terms of the related Contingent Value Rights Agreement, and the creation of additional borrowing capacity under a loan agreement to finance the transaction. Other 8-K filings discuss quarterly financial results, including revenue contributions from Afrezza, FUROSCIX, V-Go, and Tyvaso DPI–related royalties and collaborations, as well as changes in research and development and selling, general and administrative expenses.
Filings also cover MannKind’s clinical and regulatory decisions. For example, an 8-K filed in November 2025 describes the discontinuation of the Phase 3 ICoN-1 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease following a futility determination, and outlines the company’s intention to use those findings to guide ongoing development of MNKD-102, a dry powder formulation of clofazimine. Another 8-K details the first amendment to the global license and collaboration agreement with United Therapeutics, under which MannKind will formulate an additional Technosphere-based investigational product and is eligible for development milestones and royalties.
On this page, investors can review MannKind’s SEC-reported information on mergers and acquisitions, collaboration agreements, financing arrangements, and clinical program updates. Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand transaction structures, milestone obligations, and the potential impact on MannKind’s business. Users can also monitor newly posted 8-Ks and other SEC forms in near real time as they are released on EDGAR.
MannKind Corp's Chief Financial Officer Christopher B. Prentiss acquired additional company stock through a board-approved purchase plan. On March 1, 2026, he obtained 5,000 shares of common stock at $3.27 per share under the Market Price Stock Purchase Plan. Following this transaction, he directly owned 348,854 shares of MannKind common stock.
MannKind Corp Chief Executive Officer Michael Castagna reported multiple share and option acquisitions. On March 1, 2026, he acquired 15,290 shares of common stock at $3.27 per share through the company’s Market Price Stock Purchase Plan, which was approved by the board.
Following this, his direct common stock holdings rose to 2,475,911 shares. On February 26, 2026, performance milestones were reached for stock options originally granted in 2016 and 2017, leading to partial vesting of options covering 50,000, 57,750, and 37,525 shares, increasing his directly held option awards.
MannKind Corp director Steven B. Binder reported the vesting of performance-based stock options. On February 26, 2026, a defined performance milestone was achieved under an option originally granted on August 24, 2017, resulting in a grant-credited acquisition of 45,025 employee stock options at an exercise price of $0.00 per option.
Thomson David reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corp executive David Thomson reported new option vesting tied to performance goals. On February 26, 2026, 20,000 and 37,525 employee stock options (rights to buy shares) became partially vested from grants originally awarded in 2016 and 2017 after defined performance milestones were achieved.
MannKind Corp executive Stuart A. Tross reported acquisitions of both stock and options. He obtained 15,290 shares of common stock at $3.27 per share through MannKind’s Market Price Stock Purchase Plan, bringing his direct holdings to 1,000,297 common shares. He also acquired stock options for 20,000 and 28,143 shares after performance milestones from 2017 option grants were met on February 26, 2026, resulting in partial vesting of those awards.
MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, aiming to offer patient‑centric drug–device therapies for chronic conditions.
The company currently commercializes three cardiometabolic products: Afrezza inhaled insulin for adults with diabetes, Furoscix for edema in heart failure and chronic kidney disease, and the V‑Go wearable insulin delivery device. It also earns royalties and manufacturing revenue from Tyvaso DPI for pulmonary hypertension, marketed by United Therapeutics, and recently expanded this collaboration to include MNKD‑1501.
MannKind’s pipeline includes MNKD‑201, an inhaled nintedanib for idiopathic pulmonary fibrosis now in Phase 1b and global Phase 2 studies, and MNKD‑701, an early bumetanide inhalation program. Key 2026 regulatory milestones include FDA decisions on an Afrezza pediatric sBLA by May 29, 2026 and a Furoscix ReadyFlow Autoinjector sNDA by July 26, 2026.
Manufacturing is centered in Danbury, Connecticut, where Technosphere powders, inhalers and Tyvaso DPI are produced; V‑Go and many Furoscix components are made by contract manufacturers, including in China. A 2025 FDA inspection of the Connecticut facility concluded without Form 483 observations.
The filing highlights extensive risks, including dependence on United Therapeutics’ continued emphasis on Tyvaso DPI—particularly in light of its newly promoted Tresmi soft‑mist treprostinil candidate—manufacturing and supply‑chain concentration, pricing and reimbursement pressures, evolving U.S. healthcare and privacy laws, and the need for additional capital and successful commercialization to support ongoing operations and growth.
MannKind Corporation reported strong top-line growth for the fourth quarter and full year 2025, driven by its cardiometabolic and inhaled therapies portfolio. Q4 2025 revenues were $111.9 million, up 46% from Q4 2024, with full year 2025 revenues of $349.0 million, a 22% increase over 2024.
Growth came from higher royalties on Tyvaso DPI, increased collaborations and services for United Therapeutics, and rising Afrezza sales, plus $23.2 million of Furoscix revenue added after acquiring scPharmaceuticals in October 2025. Despite this, MannKind recorded a Q4 2025 net loss of $15.9 million and full year 2025 net income of $5.9 million, down from $27.6 million in 2024, as R&D and SG&A spending rose sharply to support pipeline development and the Furoscix launch.
MannKind Corporation reported an insider stock sale by Chief People & Workplace Officer Stuart A. Tross. On January 8, 2026, he sold 47,006 shares of MannKind common stock at a price of $6.33 per share. After this transaction, he continued to beneficially own 985,007 shares of common stock in direct ownership form. The filing notes that the sale occurred pursuant to a pre-established Rule 10b5-1 trading plan that was put in place on June 17, 2025, indicating the trades were scheduled in advance.
A Rule 144 notice reports a planned sale of 47,000 common shares of the issuer through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an aggregate market value of $297,510.00 and an approximate sale date of 01/08/2026. The filing states that 307,070,281 shares of this class were outstanding.
The shares to be sold were acquired as performance shares from the issuer, including 24,636 shares acquired on 05/22/2023 and 22,364 shares acquired on 05/17/2024, both listed as having payment noted as not applicable.
MannKind Corp Chief Executive Officer and director Michael Castagna reported stock option exercises and related share sales in recent insider transactions. On 12/12/2025 he exercised 20,806 employee stock options at $4.55 per share and sold 20,806 shares of common stock at $6, leaving him with 2,504,792 common shares held directly. On 12/16/2025 he exercised a further 21,310 options at $4.55 and sold 21,310 common shares at $6, again ending with 2,504,792 directly held shares. Following these trades, he beneficially owns 15,804 employee stock options with a $4.55 exercise price expiring on 05/19/2026. The transactions were carried out under a Rule 10b5-1 trading plan established on August 8, 2025.